Embecta (EMBC) Stock Forecast, Price Target & Predictions
EMBC Stock Forecast
Embecta stock forecast is as follows: an average price target of $12.00 (represents a -25.09% downside from EMBC’s last price of $16.02) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.
EMBC Price Target
The average price target for Embecta (EMBC) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential -25.09% downside from EMBC's last price of $16.02.
EMBC Analyst Ratings
According to 1 Wall Street analysts, Embecta's rating consensus is 'Sell'. The analyst rating breakdown for EMBC stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).
Embecta Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 15, 2024 | Kallum Titchmarsh | Morgan Stanley | $12.00 | $13.17 | -8.88% | -25.09% |
| Aug 16, 2022 | - | Morgan Stanley | $36.00 | $33.42 | 7.72% | 124.72% |
The latest Embecta stock forecast, released on Jul 15, 2024 by Kallum Titchmarsh from Morgan Stanley, set a price target of $12.00, which represents a -8.88% decrease from the stock price at the time of the forecast ($13.17), and a -25.09% decrease from EMBC last price ($16.02).
Embecta Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $16.02 | $16.02 | $16.02 |
| Upside/Downside | -100.00% | -25.09% | -25.09% |
In the current month, the average price target of Embecta stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Embecta's last price of $16.02. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 15, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| May 15, 2023 | Morgan Stanley | Underweight | Underweight | Hold |
| Jun 21, 2022 | Bank of America Securities | - | Underperform | Initialise |
Embecta's last stock rating was published by Morgan Stanley on Jul 15, 2024. The company gave EMBC a "Underweight" rating, the same as its previous rate.
Embecta Financial Forecast
Embecta Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $277.30M | $281.90M | - | $277.10M | $275.70M | $274.60M | $291.10M |
| Avg Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.85M | $279.18M | $281.10M | $277.25M | $276.88M | $267.44M | $264.70M | $264.92M | $271.55M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| High Forecast | $284.73M | $282.08M | $278.85M | $273.42M | $283.29M | $280.61M | $282.53M | $278.66M | $278.00M | $268.80M | $266.04M | $266.27M | $272.73M | $276.47M | $264.22M | $264.24M | $262.34M | $278.14M |
| Low Forecast | $282.28M | $279.64M | $276.45M | $271.06M | $280.85M | $278.19M | $280.09M | $276.26M | $275.75M | $266.49M | $263.75M | $263.97M | $270.38M | $274.08M | $261.94M | $261.96M | $260.08M | $275.81M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | - | 1.05% | 1.05% | 1.05% | 1.05% |
Embecta's average Quarter revenue forecast for Mar 24 based on 0 analysts is $264.70M, with a low forecast of $263.75M, and a high forecast of $266.04M. EMBC's average Quarter revenue forecast represents a -4.55% decrease compared to the company's last Quarter revenue of $277.30M (Dec 23).
Embecta EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $45.50M | $44.40M | - | $59.30M | $88.90M | $53.20M | $102.20M |
| Avg Forecast | $112.88M | $111.82M | $110.55M | $108.39M | $112.31M | $111.24M | $112.00M | $110.47M | $110.32M | $106.56M | $105.47M | $105.56M | $108.20M | $109.60M | $104.75M | $104.75M | $104.00M | $110.32M |
| High Forecast | $113.45M | $112.39M | $111.11M | $108.94M | $112.88M | $111.81M | $112.57M | $111.03M | $110.77M | $107.11M | $106.01M | $106.09M | $108.67M | $110.16M | $105.28M | $105.29M | $104.53M | $110.83M |
| Low Forecast | $112.47M | $111.42M | $110.15M | $108.00M | $111.90M | $110.84M | $111.60M | $110.08M | $109.87M | $106.18M | $105.09M | $105.18M | $107.73M | $109.21M | $104.37M | $104.38M | $103.63M | $109.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.41% | - | 0.57% | 0.85% | 0.51% | 0.93% |
0 analysts predict EMBC's average Quarter EBITDA for Mar 24 to be $105.47M, with a high of $106.01M and a low of $105.09M. This is 131.80% upper than Embecta's previous annual EBITDA (Dec 23) of $45.50M.
Embecta Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $20.10M | $6.00M | - | $14.00M | $35.20M | $-17.20M | $62.40M |
| Avg Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.54M | $34.04M | $33.39M | $32.47M | $20.94M | $26.84M | $23.14M | $26.32M | $22.99M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| High Forecast | $31.76M | $31.39M | $29.04M | $27.77M | $31.75M | $34.27M | $33.61M | $32.69M | $30.88M | $27.02M | $23.29M | $27.49M | $27.02M | $26.78M | $28.14M | $29.69M | $34.74M | $50.62M |
| Low Forecast | $31.41M | $31.04M | $28.71M | $27.46M | $31.39M | $33.88M | $33.24M | $32.32M | $15.70M | $26.71M | $23.03M | $25.15M | $21.27M | $26.48M | $27.83M | $29.36M | $34.35M | $50.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.26% | - | 0.50% | 1.19% | -0.50% | 1.24% |
Embecta's average Quarter net income forecast for Mar 24 is $23.14M, with a range of $23.03M to $23.29M. EMBC's average Quarter net income forecast represents a 15.11% increase compared to the company's last Quarter net income of $20.10M (Dec 23).
Embecta SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $90.30M | $95.70M | - | $85.20M | $72.80M | $81.90M | $83.80M |
| Avg Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $64.76M | $62.55M | $61.91M | $61.96M | $63.51M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| High Forecast | $66.60M | $65.98M | $65.22M | $63.95M | $66.26M | $65.63M | $66.08M | $65.18M | $65.02M | $62.87M | $62.23M | $62.28M | $63.79M | $64.67M | $61.80M | $61.81M | $61.36M | $65.06M |
| Low Forecast | $66.02M | $65.41M | $64.66M | $63.40M | $65.69M | $65.07M | $65.51M | $64.62M | $64.50M | $62.33M | $61.69M | $61.74M | $63.24M | $64.11M | $61.27M | $61.27M | $60.83M | $64.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.51% | - | 1.39% | 1.18% | 1.34% | 1.29% |
Embecta's average Quarter SG&A projection for Mar 24 is $61.91M, based on 0 Wall Street analysts, with a range of $61.69M to $62.23M. The forecast indicates a -31.44% fall compared to EMBC last annual SG&A of $90.30M (Dec 23).
Embecta EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | 1 | 2 | 1 | 1 | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $0.35 | $0.10 | - | $0.24 | $0.62 | $-0.30 | $1.08 |
| Avg Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.36 | $0.46 | $0.40 | $0.46 | $0.40 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| High Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.57 | $0.53 | $0.47 | $0.40 | $0.48 | $0.47 | $0.46 | $0.49 | $0.51 | $0.60 | $0.88 |
| Low Forecast | $0.54 | $0.54 | $0.50 | $0.47 | $0.54 | $0.59 | $0.57 | $0.56 | $0.27 | $0.46 | $0.40 | $0.43 | $0.37 | $0.46 | $0.48 | $0.51 | $0.59 | $0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.25% | - | 0.50% | 1.22% | -0.50% | 1.24% |
According to 0 Wall Street analysts, Embecta's projected average Quarter EPS for Mar 24 is $0.40, with a low estimate of $0.40 and a high estimate of $0.40. This represents a 14.29% increase compared to EMBC previous annual EPS of $0.35 (Dec 23).
Embecta Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| AKYA | Akoya Biosciences | $2.94 | $7.90 | 168.71% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| ATRC | AtriCure | $28.21 | $49.57 | 75.72% | Buy |
| BAX | Baxter | $39.72 | $64.62 | 62.69% | Hold |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| TFX | Teleflex | $246.05 | $304.09 | 23.59% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| WST | West Pharmaceutical Services | $300.67 | $345.33 | 14.85% | Buy |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| ALC | Alcon | $98.50 | $93.34 | -5.24% | Buy |
| RMD | ResMed | $248.93 | $209.33 | -15.91% | Hold |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| EMBC | Embecta | $16.02 | $12.00 | -25.09% | Sell |
| ATR | AptarGroup | $152.28 | $100.00 | -34.33% | Buy |
EMBC Forecast FAQ
Is Embecta a good buy?
No, according to 1 Wall Street analysts, Embecta (EMBC) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of EMBC's total ratings.
What is EMBC's price target?
Embecta (EMBC) average price target is $12 with a range of $12 to $12, implying a -25.09% from its last price of $16.02. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Embecta stock go up soon?
According to Wall Street analysts' prediction for EMBC stock, the company can go down by -25.09% (from the last price of $16.02 to the average price target of $12), down by -25.09% based on the highest stock price target, and down by -25.09% based on the lowest stock price target.
Can Embecta stock reach $20?
EMBC's average twelve months analyst stock price target of $12 does not support the claim that Embecta can reach $20 in the near future.
What are Embecta's analysts' financial forecasts?
Embecta's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $1.12B (high $1.13B, low $1.12B), average EBITDA is $446.02M (high $448.29M, low $444.43M), average net income is $131.44M (high $132.31M, low $130.83M), average SG&A $261.82M (high $263.16M, low $260.89M), and average EPS is $2.27 (high $2.29, low $2.26). EMBC's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $1.11B (high $1.12B, low $1.11B), average EBITDA is $443.64M (high $445.9M, low $442.06M), average net income is $119.17M (high $119.96M, low $118.61M), average SG&A $260.43M (high $261.75M, low $259.49M), and average EPS is $2.06 (high $2.07, low $2.05).
Did the EMBC's actual financial results beat the analysts' financial forecasts?
Based on Embecta's last annual report (Sep 2023), the company's revenue was $1.12B, beating the average analysts forecast of $1.07B by 4.51%. Apple's EBITDA was $247.8M, missing the average prediction of $427.3M by -42.01%. The company's net income was $70.4M, missing the average estimation of $107.06M by -34.24%. Apple's SG&A was $341.3M, beating the average forecast of $250.83M by 36.07%. Lastly, the company's EPS was $1.22, missing the average prediction of $1.85 by -34.08%. In terms of the last quarterly report (Dec 2023), Embecta's revenue was $277.3M, beating the average analysts' forecast of $264.92M by 4.67%. The company's EBITDA was $45.5M, missing the average prediction of $105.56M by -56.90%. Embecta's net income was $20.1M, missing the average estimation of $26.32M by -23.63%. The company's SG&A was $90.3M, beating the average forecast of $61.96M by 45.73%. Lastly, the company's EPS was $0.35, missing the average prediction of $0.455 by -23.08%